The Trump administration’s decision to impose a permanent 10% baseline tariff on imports from all countries, combined strategically with higher reciprocal tariffs on nations engaging in unfair trade practices, marks a crucial step forward in reindustrializing America and restoring economic strength and security.
CPA’s new Trade Issues and Tariff Recommendation Tracker highlights specific tariff recommendations that will produce near-term wins.
In a comment letter submitted to USTR in response to the Section 301 investigation, CPA highlighted China’s extensive use of state-driven subsidies and unfair trade practices, urging immediate implementation of targeted measures to support the revitalization of the U.S. shipbuilding industry.
Strong federal investment in the National Science Foundation and National Institutes of Health is vital for American innovation, economic growth, and national security.
For years, the de minimis loophole has flooded the U.S. with uninspected, untaxed, and often dangerous goods—from counterfeit products to fentanyl precursors fueling America’s opioid crisis.
CPA’s report demonstrates that previous tariff exemptions and exclusions significantly weakened the effectiveness of the original tariffs imposed in 2018.
President Trump’s executive order sends a clear message: The days of allowing China to weaponize US investment and financial markets against us are over.
Howard Lutnick understands that America’s trade policies must put U.S. producers, workers, and national security first. His leadership at the Commerce Department will be crucial in ensuring President Trump’s America First Trade Policy is fully implemented.
CPA announced key leadership changes as CEO Michael Stumo steps down to take on a new role in the Trump administration. Jon Toomey has been elevated as President of CPA to lead the organization and Nick Iacovella has been promoted to Executive Vice President.
For far too long, America has been at the mercy of foreign producers that routinely violate FDA safety regulations for life-saving medicines, generic drugs, and essential medical equipment.
